PNC Financial Services Group
CRVS icon

PNC Financial Services Group’s Corvus Pharmaceuticals CRVS Stock Holding History

PNC Financial Services Group’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2K Hold
137
– – ﹤0.01% 4579
2025
Q4 		$1.05K Sell
137
-162
-54% -$1.28K ﹤0.01% 4680
2025
Q3 		$2.2K Buy
+299
New +$1.53K ﹤0.01% 4474
2022
Q1 		– Sell
-3,000
Closed -$7K – 4551
2021
Q4 		$7K Buy
+3,000
New +$11.6K ﹤0.01% 3869

Other funds holding CRVS

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

PNC Financial Services Group's CRVS Position: Q1 2026 in Review

PNC Financial Services Group held its Corvus Pharmaceuticals (CRVS) position steady in Q1 2026 at 137 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #4579.

PNC Financial Services Group first reported a position in CRVS in Q4 2021 and has held it in 4 quarters since. The position peaked at $7K in Q4 2021. 164 funds tracked by Wall St. Rank hold CRVS as of Q1 2026.

  • PNC Financial Services Group held 137 shares of Corvus Pharmaceuticals worth $2K as of Q1 2026.
  • PNC Financial Services Group left its Corvus Pharmaceuticals share count unchanged in Q1 2026.
  • Corvus Pharmaceuticals made up ﹤0.01% of PNC Financial Services Group's portfolio in Q1 2026, its #4579 holding.
  • PNC Financial Services Group first reported a position in Corvus Pharmaceuticals in Q4 2021 and has held it in 4 quarters since.
  • PNC Financial Services Group's Corvus Pharmaceuticals position peaked at $7K in Q4 2021.
  • 164 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q1 2026.

Based on PNC Financial Services Group's 13F filing for Q1 2026, filed 8 May 2026.